Indian High Court rules against Bayer on Nexavar and Xarelto API exports
The Delhi High Court has allowed Alembic Pharmaceuticals (BSE: 533573) and Natco Pharma (BSE: 524816) to export sorafenib, an active ingredient in German pharma major Bayer’s (BAYN: DE) cancer drug Nexavar, and rivaroxaban, the API in its blood thinner medicine Xarelto, for research and development purposes. The patent for Nexavar and Xarelto is scheduled to end next year.
The decision is being construed as a major win for affordable medicines, as it will help develop generics in other countries, reports The Pharma Letter’s local correspondent.
A Division Bench agreed with the majority findings of an earlier Single Judge Bench that allowed exports. The former case relates to a writ petition filed by Bayer seeking to seize the consignments for export of the anti-cancer drug Sorafenib tosylate, manufactured by Natco.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze